Why did Lil­ly give tirzepatide a new name for obe­si­ty? Hint: It’s the mar­ket­ing

Eli Lil­ly’s de­ci­sion to give two dis­tinc­tive brand names to tirzepatide, which is ap­proved for type 2 di­a­betes and now chron­ic weight man­age­ment, in­di­cates just how dif­fer­ent­ly the com­pa­ny plans to mar­ket both in­di­ca­tions.

Last week it an­nounced that its weight man­age­ment ver­sion of the drug is called Zep­bound, while the same drug is brand­ed as Moun­jaro for type 2 di­a­betes.

“Pa­tients liv­ing with di­a­betes and pa­tients with obe­si­ty have dif­fer­ent needs,” a Lil­ly spokesper­son said in an email. “The dif­fer­ent brands al­low Lil­ly to ed­u­cate and pro­vide re­sources and tools in or­der for health­care pro­fes­sion­als and pa­tients to start suc­cess­ful­ly on Zep­bound.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER